Abbott clears antitrust hurdle in AMO deal
This article was originally published in The Tan Sheet
Executive SummaryWith the Jan. 5 expiration of the waiting period under the Hart-Scott-Rodino pre-merger notification program, Abbott's acquisition of Advanced Medical Optics can move forward, the pharmaceuticals and nutritionals firm says Feb. 6. Abbott has until Feb. 24 to consummate the tender offer for the eye care products company, but must also satisfy the European Commission's regulatory review. The Abbott Park, Ill.-based firm said Jan. 12 it would pay $1.36 billion for AMO's 62 million outstanding shares (1"The Tan Sheet" Jan. 19, 2009, p. 17)
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.